Aversive treatment of stimulant abuse
OwnerFrank H. Gawin, Elena Khalsa-Dennisoninventors
Life of this patent
Estimating the term…
Abstract
Psychomotor stimulant addiction in humans is treated by administering to a human patient before or during a hypodopaminergic “crash” following the psychomotor stimulant induced hyperdopaminergic high or within a period of 3 hours to 21 days prior thereto, a dosage of a pharmaceutically active neuroleptic compound effective to produce aversion to any psychomotor stimulant taken within this period.
Claims11
A method for treating psychomotor stimulant addiction comprising:
- administering a pharmaceutically active neuroleptic compound to a currently abstinent human patient at risk for relapse;
- said patient having been informed that said neuroleptic compound will produce aversive extrapyramidal symptoms upon breaking abstinence by administration of a psychomotor stimulant during the period from administering said compound up to about 21 days thereafter during which time there occurs a hypodopaminergic crash following a hypodopaminergic high induced by administration of said psychomotor stimulant;
- said neuroleptic compound being administered in a dosage sufficient to cause production of said aversive extrapyramidal symptoms upon administration of said psychomotor stimulant.
A method for treating psychomotor stimulant addiction in a currently abstinent human patient at risk for relapse which comprises the administration of both:
- a psychotherapeutic statement informing the addict they are being administered medication which will produce an aversive interaction if psychomotor stimulants are also administered;
- and
- an aversion producing dosage of a pharmaceutically active neuroleptic compound.
A method for treating cocaine addition in a human patient at risk for relapse after abstinence consolidation which comprises the administration of both:
- a prior psychotherapeutic statement informing the addict they are being administered medication which will produce an aversive interaction if cocaine is also administered;
- and
- a dosage of a flupenthixol salt or ester effective to produce aversive extrapyramidal symptoms upon interaction with the effects of cocaine taken within 3 hours to 21 days of administering said flupenthixol salt, said salt being administered, at a time within up to 21 days prior to the 3-6 hour period of hypodopaminergic crash following the hyperdopaminergic high induced by a typical 6 to 18 hour cocaine binge.
Dependencies are inferred from the claim text.